MUMBAI, INDIA, March 21, 2026
Sun Pharmaceutical Industries Limited has announced the launch of its semaglutide injection under the brand names Noveltreat and Sematrinity in India, marking a significant advancement in the treatment of type 2 diabetes and chronic weight management. The launch introduces a cost-effective GLP-1 receptor agonist therapy, designed to improve access to innovative treatments for millions of patients across India, where the burden of metabolic diseases continues to rise sharply.
Expanding Access to GLP-1 Therapies in India
The introduction of semaglutide-based therapies represents a major step in addressing the growing prevalence of diabetes and obesity, two of the most pressing public health challenges in India. Sun Pharma’s products, Noveltreat for weight management and Sematrinity for type 2 diabetes, are available in multiple dose strengths, providing flexibility for personalized treatment approaches.
Importantly, these therapies are priced significantly lower than innovator brands, with weekly treatment costs ranging between ₹750 and ₹2,000, enhancing affordability and accessibility. This pricing strategy is expected to expand patient access to advanced therapies, particularly in a market where cost remains a critical barrier to treatment adherence.
The therapies are supported by user-friendly delivery systems, including prefilled pens with concealed needles and multi-dose formats, designed to improve patient compliance, dosing accuracy, and overall treatment experience. These innovations highlight the importance of combining drug efficacy with patient-centric design in modern pharmaceutical development.
Advertisement
Addressing the Rising Burden of Diabetes and Obesity
India faces a rapidly increasing burden of metabolic disorders, with an estimated 101.3 million people living with diabetes and a growing prevalence of overweight and obesity among adults. These conditions are associated with serious complications, including cardiovascular disease, kidney failure, and increased mortality, underscoring the need for effective and scalable treatment solutions.
GLP-1 receptor agonists, such as semaglutide, have emerged as highly effective therapies for managing both diabetes and obesity, offering benefits beyond glycemic control, including weight reduction and improved cardiovascular outcomes. The availability of these therapies in India is expected to play a crucial role in improving long-term disease management and patient outcomes.
Furthermore, the launch aligns with the need for a comprehensive treatment approach, combining pharmacological interventions with lifestyle modifications, to address the complex nature of metabolic diseases. The introduction of affordable GLP-1 therapies could significantly enhance treatment adherence and disease control, particularly among underserved populations.
Strengthening Pharmaceutical Innovation and Patient Support
Sun Pharma’s launch of semaglutide products reflects its commitment to delivering high-quality, affordable medicines while leveraging its expertise in manufacturing complex pharmaceutical formulations. The company has also introduced a holistic patient support program, aimed at guiding patients throughout their treatment journey and improving overall health outcomes.
The development and distribution of these therapies involve advanced manufacturing and regulatory compliance processes, ensuring adherence to Good Manufacturing Practice (GMP) standards and maintaining product quality and safety. The use of globally sourced device technologies further enhances the reliability and performance of the delivery systems.
As the demand for innovative and accessible treatments continues to grow, the launch of Noveltreat and Sematrinity positions Sun Pharma as a key player in addressing the metabolic health crisis in India. By combining affordability, innovation, and patient-centric solutions, the company is contributing to the advancement of modern healthcare and pharmaceutical excellence.
Source: Sun Pharma press release
